Repeated significance tests of linear combinations of sensitivity and specificity of a diagnostic biomarker

被引:1
作者
Wu, Mixia [1 ]
Shu, Yu [2 ]
Li, Zhaohai [3 ]
Liu, Aiyi [4 ]
机构
[1] Beijing Univ Technol, Coll Appl Sci, Beijing 100124, Peoples R China
[2] Abbott Labs Vasc Div, 3200 Lakeside Dr, Santa Clara, CA 95054 USA
[3] George Washington Univ, Dept Stat, 801 22nd St NW, Washington, DC 20052 USA
[4] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Biostat & Bioinformat Branch, 6100 Execut Blvd, Rockville, MD 20852 USA
基金
美国国家卫生研究院;
关键词
expected sample size; inference upon early stopping; sensitivity; sequential testing; specificity; two-stage designs; type I error; Youden's index; SEQUENTIAL EVALUATION; 2-STAGE DESIGNS; ACCURACY; PREVALENCE; EFFICIENT;
D O I
10.1002/sim.6932
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
A sequential design is proposed to test whether the accuracy of a binary diagnostic biomarker meets the minimal level of acceptance. The accuracy of a binary diagnostic biomarker is a linear combination of the marker's sensitivity and specificity. The objective of the sequential method is to minimize the maximum expected sample size under the null hypothesis that the marker's accuracy is below the minimal level of acceptance. The exact results of two-stage designs based on Youden's index and efficiency indicate that the maximum expected sample sizes are smaller than the sample sizes of the fixed designs. Exact methods are also developed for estimation, confidence interval and p-value concerning the proposed accuracy index upon termination of the sequential testing. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
引用
收藏
页码:3397 / 3412
页数:16
相关论文
共 34 条
  • [1] [Anonymous], 2002, Statistical Methods in Diagnostic Medicine
  • [2] [Anonymous], 2015, Mathematical Statistics: Basic Ideas and Selected Topics
  • [3] ARMITAGE P, 1958, BIOMETRIKA, V45, P1
  • [4] Biggerstaff BJ, 2000, STAT MED, V19, P649, DOI 10.1002/(SICI)1097-0258(20000315)19:5<649::AID-SIM371>3.0.CO
  • [5] 2-H
  • [6] Incorporating toxicity considerations into the design of two-stage Phase II clinical trials
    Bryant, J
    Day, R
    [J]. BIOMETRICS, 1995, 51 (04) : 1372 - 1383
  • [7] BIVARIATE SEQUENTIAL DESIGNS FOR PHASE-II TRIALS
    CONAWAY, MR
    PETRONI, GR
    [J]. BIOMETRICS, 1995, 51 (02) : 656 - 664
  • [8] PARAMETER-ESTIMATION FOLLOWING GROUP SEQUENTIAL HYPOTHESIS-TESTING
    EMERSON, SS
    FLEMING, TR
    [J]. BIOMETRIKA, 1990, 77 (04) : 875 - 892
  • [9] HIV-1 prevalence, HIV-1 subtypes and risk factors among fishermen in the Gulf of Thailand and the Andaman Sea
    Entz, AT
    Ruffolo, VP
    Chinveschakitvanich, V
    Soskolne, V
    van Griensven, GJP
    [J]. AIDS, 2000, 14 (08) : 1027 - 1034
  • [10] Fletcher R., 1982, Clinical Epidemiology - The Essentials, V1st